SAB Biotherapeutics (NASDAQ:SABS) Earns “Buy” Rating from Chardan Capital

Chardan Capital restated their buy rating on shares of SAB Biotherapeutics (NASDAQ:SABS) in a report released on Tuesday, Benzinga reports. The brokerage currently has a $25.00 price objective on the stock.

Separately, HC Wainwright dropped their target price on shares of SAB Biotherapeutics from $10.00 to $6.00 and set a buy rating for the company in a report on Tuesday, April 2nd.

SAB Biotherapeutics Trading Down 4.1 %

SABS opened at $4.41 on Tuesday. The company has a quick ratio of 5.45, a current ratio of 5.45 and a debt-to-equity ratio of 0.06. SAB Biotherapeutics has a twelve month low of $4.00 and a twelve month high of $11.90. The company has a 50-day simple moving average of $4.92 and a 200 day simple moving average of $3.13.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in SABS. Vanguard Group Inc. lifted its holdings in shares of SAB Biotherapeutics by 5.6% in the first quarter. Vanguard Group Inc. now owns 721,151 shares of the company’s stock worth $2,712,000 after acquiring an additional 38,179 shares during the last quarter. State Street Corp increased its stake in shares of SAB Biotherapeutics by 244.2% in the first quarter. State Street Corp now owns 42,341 shares of the company’s stock valued at $159,000 after buying an additional 30,041 shares during the period. Millennium Management LLC acquired a new position in shares of SAB Biotherapeutics in the second quarter valued at approximately $93,000. Citadel Advisors LLC acquired a new position in shares of SAB Biotherapeutics in the third quarter valued at approximately $28,000. Finally, HighTower Advisors LLC acquired a new position in shares of SAB Biotherapeutics in the fourth quarter valued at approximately $44,000. Institutional investors own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.